BCRX Biocryst Pharmaceuticals Inc.
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
- 0 P/E
- 40.98 P/S
- 9.20 P/B
- -0.613 EPS
- -118.77% Cash ROIC
- 2.49 Cash Ratio
- 0.00 / N/A % Dividend
- 857,055.00 Avg. Vol.
- 55.22M Shares
- 754.6M Market Cap.
BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com...
Markets Wired - Jan 29, 2015
Seeking Alpha (registration) - Jan 27, 2015
FDA Grants Fast Track Designation for BCX4161 for the Treatment of Hereditary ... - CNNMoney
Bar and Graph Report - 48 minutes ago
Markets Wired - Jan 21, 2015
BioCryst Pharmaceuticals, Inc. Price Target Update - Bar and Graph Report
Stafford Daily - Jan 22, 2015
Markets Wired - Jan 12, 2015
Shares Outperform Index: Ship Finance International Ltd , BioCryst ... - Rock Hill Daily
TheStreet.com - Dec 26, 2014
Motley Fool - May 27, 2014
BioCryst Announces Positive Results From OPuS-1, a Phase 2 Trial of BCX4161 ... - MarketWatch
Ashburn Daily - Jan 22, 2015
Stafford Daily - Jan 13, 2015
Pre-market Bullish Movers: Himax Technologies (ADR) (NASDAQ:HIMX ... - Property Mentor